DiaMedica Therapeutics Inc. Q2 FY2025 earnings call

• Preeclampsia program: In July, announced positive interim results from Part 1a of Phase II trial for DM199, showing significant reductions in systolic and diastolic blood pressure, safety, and improved uterine artery blood flow. Advancing to Cohort 10 in Part 1a, with Part 1b, Part 2, and Part 3 cohorts planned.
• Stroke program: Poster presented at European Stroke Organization Conference on ReMEDy1 trial, ReMEDy2 trial enrollment ongoing, interim analysis of first 200 patients expected in Q2 2026, DSMB meeting positive.
• Private placement: Completed $30 million private placement, extending cash runway into H2 2027.
• Index inclusion: Added to U.S. small-cap Russell 2000 and Russell 3000 indexes.
• New CMO: Dr. Julie Krop joined, bringing experience in biopharma and preeclampsia drug development.

As of June 30, 2025, cash, cash equivalents and short-term investments were $30 million, compared to $44.1 million as of December 31, 2024. Pro forma cash position with net proceeds from the July private placement is approximately $60 million. R&D expenses for the 3 months ended June 30, 2025 were $5.8 million, up from $3.9 million in the same period in 2024. General and administrative expenses for the 3 months ended June 30, 2025 were $2.2 million, up from $1.7 million in the same period in 2024. Net losses for the 3 months ending June 30, 2025 were $7.7 million, higher than the $5.1 million reported in the same period in 2024.

• Preeclampsia: Moving into Cohort 10 of Part 1b starting next week, planning to finalize dosing regimens for Part 1b, Part 2, and Part 3.
• U.S. Phase IIb study: Preparing to file pre-IND request to FDA, planning to start study next year after IND, finalizing protocol.

Q: Thomas Flaten asks Julie Krop about joining the company and thoughts on stroke program.

A: Julie Krop mentions commitment to women's health, excitement about programs and team, de-risked biology of DM199.

Q: Thomas Flaten asks Rick Pauls about preeclampsia cohort calendar and U.S. Phase IIb study target indication.

A: Rick Pauls talks about Cohort 10 starting next week, Part 1b advancement, U.S. Phase IIb study targeting expected management in preeclampsia.

Q: Chase Knickerbocker asks about stroke study enrollment sites and U.S. Phase IIb primary endpoint.

A: Rick Pauls mentions 40 active sites, U.K. and Europe sites coming on board, and need to finalize protocol for U.S. Phase IIb primary endpoint.